hLL2 (epratuzumab)

DRUG2 trials

Sponsors

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Gilead Sciences

Conditions

Non-Hodgkins LymphomaSystemic Lupus Erythematosus

Phase 1

Humanized LL2IGG to Treat Systemic Lupus Erythematosus

CompletedNCT00011908

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Systemic Lupus Erythematosus

Start: 2001-02-28End: 2003-01-31Target: 20Updated: 2008-03-04

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

TerminatedNCT00054834

Gilead SciencesNon-Hodgkins Lymphoma

Start: 2003-03-31Target: 27Updated: 2021-08-16